Mauna Kea Technologies Expands International Adoption of Cellvizio® for Pancreatic Cystic Lesions with Key Hospital Installations in Spain and the United Arab Emirates

Resumen detallado
PARIS & BOSTON, November 19, 2026--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announces the clinical deployment of Cellvizio® for improved pancreatic cyst characterization at two flagship institutions: Centro Médico Teknon in Barcelona, the first hospital in Spain, and…
Centro Médico Teknon in Barcelona, a flagship of Spain's leading private hospital group Quirónsalud now offers enhanced characterization of pancreatic cysts with Cellvizio
King's College Hospital London in Dubai is the first hospital in the MENA region to offer Cellvizio for improved detection of early pancreatic cancer
These two key installations mark World Pancreatic Cancer Day, addressing one of the world's deadliest cancers, causing nearly 490,000 deaths1 annually
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announces the clinical deployment of Cellvizio® for improved pancreatic cyst characterization at two flagship institutions: Centro Médico Teknon in Barcelona, the first hospital in Spain, and King's College Hospital London in Dubai, the first hospital in the Middle East and North Africa (MENA) region, marking World Pancreatic Cancer Day.
As the sixth leading cause of cancer mortality worldwide, with an estimated 531,000 new cases and nearly 490,000 deaths annually1, pancreatic cancer carries a five-year survival rate below 10%2, making quick characterization of pancreatic cystic lesions critical. Although CT and MRI scans incidentally detect pancreatic cysts in 3% to 10% of adults3 (and 10% to 20% over age 704), conventional work-up often falls short: up to 30% of cysts remain indeterminate after endoscopic ultrasound5 and over 50% of fine-needle cytology aspirations are inconclusive6.
Included in the European Society of Gastrointestinal Endoscopy (ESGE) guidelines8, EUS-nCLE with Cellvizio® resolves this impasse by allowing the endoscopist to pass a microscopic optical probe through the puncture needle in order to visualize the cyst's cellular lining in real time and thus to differentiate precancerous mucinous lesions from benign cysts with 96% accuracy and to cut unnecessary surgeries by over 40%9.
In Spain, Dr. Gonzalo López Roldán…
Inicio del artículo, extracto de Yahoo Finance. Para leer el resto, abra el artículo en el sitio del medio.
MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (finance.yahoo.com)




